Literature DB >> 2784737

Suppression of polyclonal B cell proliferation mediated by supernatants from human myeloma bone marrow cell cultures.

D Peest1, R Hölscher, R Weber, R Leo, H Deicher.   

Abstract

For functional characterization and semi-quantitative estimation of soluble regulator factors influencing polyclonal B cell proliferation and differentiation, we established two assays. One of the assays measures enhancement or inhibition of proliferation from purified human spleen B lymphocytes, and the other one the effect of soluble factors on CESS-cell differentiation. We found no difference concerning regulator factors for B cell differentiation between bone marrow cell culture supernatants from multiple myeloma (MM) patients and from controls, whereas significantly higher suppressor activity on polyclonal B cell proliferation could be detected in the former group of supernatants. The extent of such determined suppressor activity in vitro correlated with the amount of polyclonal serum IgM of the corresponding patients. These results indicate that one or several soluble suppressor factors may be involved in immunoregulatory mechanisms responsible for the humoral immunodeficiency observed in MM patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784737      PMCID: PMC1542115     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  INFECTION, ANTIBODY RESPONSE AND GAMMA GLOBULIN COMPONENTS IN MULTIPLE MYELOMA AND MACROGLOBULINEMIA.

Authors:  J L FAHEY; R SCOGGINS; J P UTZ; C F SZWED
Journal:  Am J Med       Date:  1963-11       Impact factor: 4.965

2.  Monocyte-mediated suppression of human B lymphocyte differentiation in vitro.

Authors:  W Knapp; G Baumgartner
Journal:  J Immunol       Date:  1978-09       Impact factor: 5.422

3.  Infections complicating multiple myeloma and chronic lymphocytic leukemia.

Authors:  J J Twomey
Journal:  Arch Intern Med       Date:  1973-10

4.  Isotype-specific suppression of IgA: suppression of IgA responses in BALB/c mice by T alpha cells.

Authors:  R G Hoover; R G Lynch
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

5.  Origin and function of suppressor macrophages in myeloma.

Authors:  J Kennard; S Zolla-Pazner
Journal:  J Immunol       Date:  1980-01       Impact factor: 5.422

6.  Suppression of polyclonal immunoglobulins in multiple myeloma: relationship to the staging and other manifestations at diagnosis.

Authors:  W Pruzanski; M S Gidon; A Roy
Journal:  Clin Immunol Immunopathol       Date:  1980-10

7.  Enhanced T cell suppression is directed toward sensitive circulating B cells in multiple myeloma.

Authors:  R T Perri; M M Oken; N E Kay
Journal:  J Lab Clin Med       Date:  1982-04

8.  Suppressor activity of splenic macrophages in murine plasmacytoma (PC) is inhibited by PC specific ligands.

Authors:  Y H Chen; P Heller
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

9.  In vitro production of monoclonal and polyclonal immunoglobulins by peripheral blood mononuclear cells in human plasma cell myeloma.

Authors:  D Peest; G Holm; H Mellstedt; D Pettersson
Journal:  Scand J Immunol       Date:  1982-06       Impact factor: 3.487

10.  Hypogammaglobulinemia in experimental myeloma: the role of suppressor factors from mononuclear phagocytes.

Authors:  R S Krakauer; W Strober; T A Waldmann
Journal:  J Immunol       Date:  1977-04       Impact factor: 5.422

View more
  1 in total

1.  Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.

Authors:  E Kastritis; F Zagouri; A Symeonidis; M Roussou; A Sioni; A Pouli; S Delimpasi; E Katodritou; E Michalis; M Michael; E Hatzimichael; A Vassou; P Repousis; A Christophoridou; Z Kartasis; E Stefanoudaki; C Megalakaki; S Giannouli; M-C Kyrtsonis; K Konstantopoulos; M Spyroupoulou-Vlachou; E Terpos; M A Dimopoulos
Journal:  Leukemia       Date:  2014-03-18       Impact factor: 11.528

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.